| MR编号 | NL/H/4508/005 |
|---|
| 药品名称 | Dailiport 5 mg |
|---|
| 活性成分 | - Tacrolimus monohydrate 5.0 mg
|
|---|
| 剂型 | Prolonged-release capsule, hard |
|---|
| 上市许可持有人 | Sandoz B.V.
Hospitaaldreef 29
1315 RC Almere
Nederland |
|---|
| 参考成员国 - 产品名称 | Netherlands (NL) Dailiport 5 mg, harde capsules met verlengde afgifte RVG 123569 |
|---|
| 互认成员国 - 产品名称 | - Denmark (DK)
Dailiport - Belgium (BE)
Dailiport 5 mg capsules met verlengde afgifte - Iceland (IS)
Dailiport forðahylki - United Kingdom (Northern Ireland) (XI)
- Austria (AT)
Dailiport 5 mg - Hartkapseln, retardiert - Portugal (PT)
- Sweden (SE)
- Norway (NO)
Dailiport - Finland (FI)
- Poland (PL)
Dailiport - Latvia (LV)
Dailiport 5 mg ilgstošās darbības cietās kapsulas - Lithuania (LT)
Dailiport 5 mg pailginto atpalaidavimo kietosios kapsulės - Estonia (EE)
DAILIPORT - Czechia (CZ)
Dailiport - Slovakia (SK)
Dailiport 5 mg - Slovenia (SI)
Dailiport 5 mg trde kapsule s podaljšanim sproščanjem - Germany (DE)
Dailiport 5 mg Hartkapseln, retardiert
|
|---|
| 许可日期 | 2019/09/18 |
|---|
| 最近更新日期 | 2025/02/03 |
|---|
| 药物ATC编码 | |
|---|
| 申请类型 | - TypeLevel1：Abridged
- TypeLevel2：Additional Strength/Form
- TypeLevel3：Generic Art 10.1 and 10.2 Dir 2001/83/EC
- TypeLevel4：Chemical Substance
- TypeLevel5：Prescription Only
|
|---|
| 附件文件下载 | |
|---|
| 市场状态 | Positive |
|---|